VCEL Stock Shows Significant Volatility with 52-Week High of $63
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Should l Buy VCEL?
Source: NASDAQ.COM
- Stock Price Analysis: VCEL's 52-week low is $29.24, with a high of $63, and the last trade at $38.11 indicates significant volatility over the past year, reflecting varying market expectations regarding its future performance.
- Market Trend Observation: The current price of $38.11 is close to the 52-week low, suggesting a cautious investor sentiment towards the company's growth prospects, while potentially providing a window for buying opportunities.
- Technical Indicator Focus: VCEL's stock has crossed above its 200-day moving average, indicating a possible short-term rebound trend that has caught the attention of technical analysts, which may influence investor trading decisions.
- Investor Sentiment Assessment: Despite the current price being below the 52-week high, market views on VCEL remain diverse, necessitating investors to monitor fundamental changes in the company to make more informed investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VCEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VCEL
Wall Street analysts forecast VCEL stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 30.550
Low
55.00
Averages
57.67
High
60.00
Current: 30.550
Low
55.00
Averages
57.67
High
60.00
About VCEL
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vericel Receives Approval for MACI Commercial Production
- Regulatory Milestone: Vericel Corporation has received FDA approval to commence commercial manufacturing of MACI® at its state-of-the-art facility in Burlington, Massachusetts, marking a significant achievement in complex cell therapy manufacturing, with production expected to start in Q2 2026.
- Capacity Expansion: This approval enables Vericel to increase production capacity for its restorative cartilage repair product to meet rising market demand, further solidifying its leadership position in the sports medicine and severe burn care markets.
- Supply Chain Enhancement: The new facility's operational launch will strengthen the company's supply chain capabilities, supporting its mission to deliver innovative, high-quality therapies to patients while laying a foundation for long-term value creation for shareholders.
- International Market Potential: With the commercialization of MACI, Vericel plans to expand its reach into markets outside the U.S., further broadening its global business and seizing growth opportunities in international markets.
See More
Vericel Corporation Reports Strong Q4 2025 Earnings with Record Revenue Growth
- Record Financial Performance: Vericel Corporation reported fourth quarter total revenue of $92.9 million, reflecting a 23% year-over-year growth, with full-year revenue reaching $276.3 million, exceeding expectations and showcasing the company's strong market performance and profitability.
- Significant MACI Sales Growth: The MACI product line generated over $84.1 million in revenue during Q4, marking a 23% increase compared to the previous year and a 51% sequential growth, indicating substantial progress in expanding market share and product acceptance.
- Strategic Investments and Expansion: The company plans to continue expanding its MACI sales force in 2026 while advancing the MACI Ankle clinical study and international market expansion, with projected MACI revenue guidance of $280 million to $286 million for the full year, reflecting confidence in future growth.
- Cash Flow and Financial Health: By the end of 2025, the company reported approximately $200 million in cash and investments with no debt, alongside an operating cash flow of $52 million for the year, demonstrating robust financial management and operational efficiency.
See More
Vericel Q4 Earnings Exceed Expectations with Strong Revenue Growth
- Strong Earnings Report: Vericel's Q4 GAAP EPS of $0.45 beats expectations by $0.06, indicating a sustained enhancement in profitability and reflecting the company's competitive position in the market.
- Significant Revenue Growth: The total revenue reached $92.92 million, representing a 23.2% year-over-year increase and surpassing market expectations by $0.26 million, showcasing Vericel's success in product demand and market expansion.
- MACI Revenue Performance: MACI® net revenue grew by 23% to $84.1 million, further solidifying its market position in regenerative medicine and is expected to drive future revenue growth.
- Future Financial Guidance: Vericel anticipates total revenue between $316 million and $326 million for 2026, with MACI revenue projected between $280 million and $286 million, demonstrating the company's confidence and strategic planning for future growth.
See More
Vericel Corporation (VCEL) Expects $276 Million Revenue in 2025 with Continued Profitability
- Financial Outlook: Vericel anticipates total net revenue of approximately $276 million for 2025, with MACI net revenue of $239.5 million, reflecting a 23% growth in Q4, indicating sustained competitive strength in the market.
- Profitability Improvement: The company expects to achieve GAAP net income profitability for the second consecutive year, supported by a gross margin of 74%, which will provide robust financial backing for future investments and expansions.
- Operational Achievements: Vericel has reached a quarterly record in MACI implants and trained surgeons, with over 900 MACI-trained surgeons, and plans to commence commercial manufacturing in a new facility in 2026, showcasing strong growth potential.
- Market Performance: Despite a downturn in the broader market, Vericel's stock rose 2.92% to $37.66, reflecting unique company-specific momentum, although the stock has decreased by 36.77% over the past 12 months.
See More
VCEL Stock Shows Significant Volatility with 52-Week High of $63
- Stock Price Analysis: VCEL's 52-week low is $29.24, with a high of $63, and the last trade at $38.11 indicates significant volatility over the past year, reflecting varying market expectations regarding its future performance.
- Market Trend Observation: The current price of $38.11 is close to the 52-week low, suggesting a cautious investor sentiment towards the company's growth prospects, while potentially providing a window for buying opportunities.
- Technical Indicator Focus: VCEL's stock has crossed above its 200-day moving average, indicating a possible short-term rebound trend that has caught the attention of technical analysts, which may influence investor trading decisions.
- Investor Sentiment Assessment: Despite the current price being below the 52-week high, market views on VCEL remain diverse, necessitating investors to monitor fundamental changes in the company to make more informed investment decisions.
See More
American Express and Snowflake See Significant Options Trading Volume Surge
- American Express Options Trading: American Express (AXP) saw options trading volume reach 12,030 contracts, equivalent to approximately 1.2 million shares, representing about 47.1% of its average daily trading volume of 2.6 million shares over the past month, indicating heightened market interest in its future performance.
- High Strike Call Options: The $382.50 strike call option expiring on December 26, 2025, recorded a trading volume of 1,611 contracts today, representing around 161,100 underlying shares, suggesting increased investor expectations for a rise in American Express's stock price.
- Snowflake Options Trading: Snowflake (SNOW) experienced options trading volume of 29,100 contracts, translating to approximately 2.9 million shares, or about 45% of its average daily trading volume of 6.5 million shares over the past month, reflecting strong market confidence in its growth prospects.
- High Strike Call Options: The $225 strike call option expiring on December 26, 2025, saw a trading volume of 2,751 contracts today, equivalent to approximately 275,100 underlying shares, indicating optimistic sentiment among investors regarding Snowflake's future performance.
See More
Vericel Receives Approval for MACI Commercial Production
- Regulatory Milestone: Vericel Corporation has received FDA approval to commence commercial manufacturing of MACI® at its state-of-the-art facility in Burlington, Massachusetts, marking a significant achievement in complex cell therapy manufacturing, with production expected to start in Q2 2026.
- Capacity Expansion: This approval enables Vericel to increase production capacity for its restorative cartilage repair product to meet rising market demand, further solidifying its leadership position in the sports medicine and severe burn care markets.
- Supply Chain Enhancement: The new facility's operational launch will strengthen the company's supply chain capabilities, supporting its mission to deliver innovative, high-quality therapies to patients while laying a foundation for long-term value creation for shareholders.
- International Market Potential: With the commercialization of MACI, Vericel plans to expand its reach into markets outside the U.S., further broadening its global business and seizing growth opportunities in international markets.
See More
Vericel Corporation Reports Strong Q4 2025 Earnings with Record Revenue Growth
- Record Financial Performance: Vericel Corporation reported fourth quarter total revenue of $92.9 million, reflecting a 23% year-over-year growth, with full-year revenue reaching $276.3 million, exceeding expectations and showcasing the company's strong market performance and profitability.
- Significant MACI Sales Growth: The MACI product line generated over $84.1 million in revenue during Q4, marking a 23% increase compared to the previous year and a 51% sequential growth, indicating substantial progress in expanding market share and product acceptance.
- Strategic Investments and Expansion: The company plans to continue expanding its MACI sales force in 2026 while advancing the MACI Ankle clinical study and international market expansion, with projected MACI revenue guidance of $280 million to $286 million for the full year, reflecting confidence in future growth.
- Cash Flow and Financial Health: By the end of 2025, the company reported approximately $200 million in cash and investments with no debt, alongside an operating cash flow of $52 million for the year, demonstrating robust financial management and operational efficiency.
See More
Vericel Q4 Earnings Exceed Expectations with Strong Revenue Growth
- Strong Earnings Report: Vericel's Q4 GAAP EPS of $0.45 beats expectations by $0.06, indicating a sustained enhancement in profitability and reflecting the company's competitive position in the market.
- Significant Revenue Growth: The total revenue reached $92.92 million, representing a 23.2% year-over-year increase and surpassing market expectations by $0.26 million, showcasing Vericel's success in product demand and market expansion.
- MACI Revenue Performance: MACI® net revenue grew by 23% to $84.1 million, further solidifying its market position in regenerative medicine and is expected to drive future revenue growth.
- Future Financial Guidance: Vericel anticipates total revenue between $316 million and $326 million for 2026, with MACI revenue projected between $280 million and $286 million, demonstrating the company's confidence and strategic planning for future growth.
See More
Vericel Corporation (VCEL) Expects $276 Million Revenue in 2025 with Continued Profitability
- Financial Outlook: Vericel anticipates total net revenue of approximately $276 million for 2025, with MACI net revenue of $239.5 million, reflecting a 23% growth in Q4, indicating sustained competitive strength in the market.
- Profitability Improvement: The company expects to achieve GAAP net income profitability for the second consecutive year, supported by a gross margin of 74%, which will provide robust financial backing for future investments and expansions.
- Operational Achievements: Vericel has reached a quarterly record in MACI implants and trained surgeons, with over 900 MACI-trained surgeons, and plans to commence commercial manufacturing in a new facility in 2026, showcasing strong growth potential.
- Market Performance: Despite a downturn in the broader market, Vericel's stock rose 2.92% to $37.66, reflecting unique company-specific momentum, although the stock has decreased by 36.77% over the past 12 months.
See More
VCEL Stock Shows Significant Volatility with 52-Week High of $63
- Stock Price Analysis: VCEL's 52-week low is $29.24, with a high of $63, and the last trade at $38.11 indicates significant volatility over the past year, reflecting varying market expectations regarding its future performance.
- Market Trend Observation: The current price of $38.11 is close to the 52-week low, suggesting a cautious investor sentiment towards the company's growth prospects, while potentially providing a window for buying opportunities.
- Technical Indicator Focus: VCEL's stock has crossed above its 200-day moving average, indicating a possible short-term rebound trend that has caught the attention of technical analysts, which may influence investor trading decisions.
- Investor Sentiment Assessment: Despite the current price being below the 52-week high, market views on VCEL remain diverse, necessitating investors to monitor fundamental changes in the company to make more informed investment decisions.
See More
American Express and Snowflake See Significant Options Trading Volume Surge
- American Express Options Trading: American Express (AXP) saw options trading volume reach 12,030 contracts, equivalent to approximately 1.2 million shares, representing about 47.1% of its average daily trading volume of 2.6 million shares over the past month, indicating heightened market interest in its future performance.
- High Strike Call Options: The $382.50 strike call option expiring on December 26, 2025, recorded a trading volume of 1,611 contracts today, representing around 161,100 underlying shares, suggesting increased investor expectations for a rise in American Express's stock price.
- Snowflake Options Trading: Snowflake (SNOW) experienced options trading volume of 29,100 contracts, translating to approximately 2.9 million shares, or about 45% of its average daily trading volume of 6.5 million shares over the past month, reflecting strong market confidence in its growth prospects.
- High Strike Call Options: The $225 strike call option expiring on December 26, 2025, saw a trading volume of 2,751 contracts today, equivalent to approximately 275,100 underlying shares, indicating optimistic sentiment among investors regarding Snowflake's future performance.
See More
